68 results about "Gangliosidosis" patented technology

The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and / or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumor cells.

The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.

The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes.

Modified polypeptides based on the botulinum neurotoxin A heavy chain containing the double mutation Trp-Tyr->Leu-Ser in the ganglioside binding motif Ser-X-Trp-Tyr do not bind polysialogangliosides and nerve endings. The polypeptides are useful in the preparation of nontoxic vaccines against the effects of C. botulinum infection. The modified polypeptides are also useful as vehicles for the transepithelial delivery of diagnostic and therapeutic entities, through formation of conjugates between the polypeptides and the diagnostic or therapeutic entities.

Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular / metabolic alterations of phospholipid and ganglioside metabolisms.

Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.

During the growth and study of NSCs, a range of molecules present on the surface of multipotent neural stem and progenitor cells (NSCs) were identified. These markers were identified using a number of human and murine neural stem cell lines, including retinal stem cells (RSCs). The NSC-specific markers identified included gene products as well as non-protein molecules and sugar epitopes not directly coded in the genome. Together with surface markers which were determined to be absent from the surface of hNSCs, the molecules described herein provide a means to enrich for neural stem cells, or neural progenitor subpopulations, particularly using combinatorial cell sorting strategies. These same molecules also represent targets for pharmacological manipulation of NSC populations and subpopulations, both in vivo and ex vivo. Furthermore, these molecules provide potential targets for therapeutic manipulation of other neural precursor-related cell types including malignant cell types as well as diseases originating from, or preferentially affecting, various uncommitted or replication-competent cell types.

The present invention generally provides compositions methods and composition relating to the diagnosis and / or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and / or a de-N-acetylated sialic acid-modified cell surface protein.

Modified polypeptides based on the botulinum neurotoxin A heavy chain containing the double mutation Trp-Tyr->Leu-Ser in the ganglioside binding motif Ser-X-Trp-Tyr do not bind polysialogangliosides and nerve endings. The polypeptides are useful in the preparation of nontoxic vaccines against the effects of C. botulinum infection. The modified polypeptides are also useful as vehicles for the transepithelial delivery of diagnostic and therapeutic entities, through formation of conjugates between the polypeptides and the diagnostic or therapeutic entities.

The present invention relates to a medicine formed from ganglioside and ginkgo leaf extract and its healht-care product and application. The animal experiments and clinical trials show that the medicine and health-care product possess good synergistic action, and can obtain obvious effect for curing and preventing senile dementia, preventing and curing Parkinson's disease, curing and preventing ischemic cerebrovascular disease, and have the functions of delaying senility and raising resistance to fatigue and learning memory.

During the growth and study of NSCs, a range of molecules present on the surface of multipotent neural stem and progenitor cells (NSCs) were identified. These markers were identified using a number of human and murine neural stem cell lines, including retinal stem cells (RSCs). The NSC-specific markers identified included gene products as well as non-protein molecules and sugar epitopes not directly coded in the genome. Together with surface markers which were determined to be absent from the surface of hNSCs, the molecules described herein provide a means to enrich for neural stem cells, or neural progenitor subpopulations, particularly using combinatorial cell sorting strategies. These same molecules also represent targets for pharmacological manipulation of NSC populations and subpopulations, both in vivo and ex vivo. Furthermore, these molecules provide potential targets for therapeutic manipulation of other neural precursor-related cell types including malignant conditions as well as other diseases originating from, or preferentially affecting, various uncommitted or replication-competent cell types.

The present invention relates to a method for producing glycolipides substance using ganglioside as main component, sand method includes the following steps: pulverizing animal brain tissue, adding 20-100% alcohol solvent to make extraction, in which the ratio of dose of alcohol and weight of brain tissue is 1-10:1, filtering or centrifugalizing, concentrating filtrate, the concentrate and its freeze-dried powder can be diluted with water or mixed with edible auxiliary material, and can be made into the oral brain health-care product with various forms.

During the growth and study of NSCs, a range of molecules present on the surface of multipotent neural stem and progenitor cells (NSCs) were identified. These markers were identified using a number of human and murine neural stem cell lines, including retinal stem cells (RSCs). The NSC-specific markers identified included gene products as well as non-protein molecules and sugar epitopes not directly coded in the genome. Together with surface markers which were determined to be absent from the surface of hNSCs, the molecules described herein provide a means to enrich for neural stem cells, or neural progenitor subpopulations, particularly using combinatorial cell sorting strategies. These same molecules also represent targets for pharmacological manipulation of NSC populations and subpopulations, both in vivo and ex vivo. Furthermore, these molecules provide potential targets for therapeutic manipulation of other neural precursor-related cell types including malignant conditions as well as other diseases originating from, or preferentially affecting, various uncommitted or replication-competent cell types.

This invention discloses a method for extracting ganglioside from animal tissue. The method comprises: extracting ganglioside from animal tissue by using acetone, THF, methanol, chloroform or other polar solvents in buffer containing Na2HPO4, NaH2PO4 or citric acid. During the whole process, ion-exchange water (free of heavy metals) is used, and the treatment temperature is controlled below 35 deg.C to reduce or avoid physiological activity loss. The product is crude ganglioside with some other glycolipids, and has healthcare function.

Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.

The invention relates to a method for preparing mono sialic acid hexose ganglioside sodium agent, comprising removing integument and blood vessel from the fresh or frozen pig brain or cattle brain, pushing for dewatering with cold acetone for several times, filtering with organic membrane, pouring out the acetone, and treating into acetone powder, packing, and conserving; extracting clarified solution from acetone powder, filtering with ultra-filter membrane and getting ultra-filtrate, extracting with tobacco extract, sodium filtering with sodium filter membrane to remove small molecule, abandoning the filtrate, getting clean condensed liquid of the mono sialic acid hexose ganglioside sodium agent; sterilizing and getting the refine product. The invention changes the polarity of the extracting organic solvent, which makes the ganglioside be released almost fully into the solution. The invention employs the ionic sodium filter membrane to separate and converse the ganglioside depending on the its number difference in sialic acid and carboxyl groups, and employs modern membrane separation technique to replace filling material and column suction technique, which saves large quantity of solvent and time, and increases productivity.

The present invention discloses a method for extracting ganglioside from animal tissue. Said method adopts one kind of several kinds of polar solvents matched with polarity of ganglioside to greatly raise extraction efficiency of ganglioside, and adopts inversed phase extraction method to remove impurity from the extract to raise product grade and reduce production cost. The purity of the ganglioside prepared by using said invented method can be up to 81%, and its cholesterol and neutral lipide contents are low. Said invention is simple in production process, suitable for scale production, its product purity is high, and can meet the food and medicinal requirements.

Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and / or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

The present invention relates to applications of a group of ganglioside derivatives containing unsaturated fatty acid chains in promotion of neurite growth. According to the present invention, the library of ganglioside derivatives containing unsaturated fatty acid chains is synthesized through a sphingolipid ceramide N-deacylase method, and is combined with the classical neurite growth promotioncell model; and the results show that the ganglioside derivatives containing unsaturated fatty acid chains have the significantly-improved biological activity of the neurite growth promotion, and thedifferent number of the carbon chains of the ganglioside sphingosine base can significantly affect the biological activity of the neurite growth promotion.

The invention discloses a kind of compound medicine which contains active polypeptide extracted from muscle organism of mammal except human and ganglioside extracted from brain organism of mammal except human. The weight of polypeptide is 6.1-100 times than the sialinic acid in ganglioside. The invention also discloses the manufacturing method and the application in the production of medicine for curing SARS and the heart and brain syndrome caused by SARS. The medicine in the invention can improve metabolism of the heart and brain organism, take part in the growth, differentiation and regeneration of nerve cell in brain, improve the blood circulation of brain and metabolism function of brain, it can cure functional disorder caused by cardiac muscle and brain disease.

The present invention is one kind of ganglioside and bean food composition and its application in delaying senility and improving memory. Based on the modern health care theory of homologous food andmedicine, the present invention combines the main nutritious components of ganglioside and bean food and provides the bean food with ganglioside. Experiment shows that the composition has strong effect of reducing peroxidation of lipoid and that fruit fly taking the said composition has obvious prolonged life and Wistar rat taking the said composite has obviously improved learning and memory capacity. The composition is safe and has no toxicity.

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The invention discloses a method for preparing cerebroside carnosine solution and relative cerebroside carnosine injection, wherein the cerebroside carnosine injection contains ganglioside and natural active peptide prepared by present biological purifying technique. And the inventive method comprises that using non-cow animal brain as material, using chloroform / carbinol mixture solvent to obtain the extractive solution with ganglioside from the brain, wherein the volume ratio of the chloroform / carbinol mixture solvent is 1-2:1, then preparing the extractive solution of small molecule peptide whose molecule weight is lower than 8000 from the muscle of non-cow animal, mixing the extractive solutions of step 1 and step 2, while the ganglioside: small molecule peptide is (85-115 mu g) :(5.44-7.36mg). The inventive injection can be used to treat cerebral infarction, coronary disease effectively or the like.

Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant.The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3 / VSSP and N-GcGM3 / VSSP, showing advantages due to the less aggressive reaction in the site of injection and can be used in a simpler way and better for the patients.

The invention discloses sialidase with metal ion tolerance, heat stability and acid stability. The amino acid sequence of the sialidase is as shown in SEQ ID No. 1 or is an amino acid sequence obtained through deletion and mutation of SEQ ID No. 1 and maintaining unchanged sialidase functions; and the amino acid sequence is purified after expression by Escherichia coli. The sialidase provided by the invention has strong tolerance to divalent metal ions, heat stability and acid stability, can hydrolyze substrates in the connection forms of alpha-2,3 and alpha-2,6 and realizes biotransformation of total gangliosides extracted from pig brains for preparation of high-purity GM1; meanwhile, it is found out for the first time that the sialidase can inhibit migration of bladder cancer cells by transforming ganglioside on the surface of the cancer cells into GM1, so the sialidase has important application prospects.

This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.

The invention relates to a glioma tumor marker and an application thereof. The glioma tumor marker is disialyl ganglioside, and the structure of the marker is represented by one or more of NeuAc-alpha3-Gal-beta3-GalNAc-beta4(NeuAc-alpha3)-Gal-beta4-Glu-Cer, Gal-beta3-GalNAc-beta4(NeuAc-alpha8-NeuAc-alpha3)-Gal-beta4-Glu-Cer, GalNAc-beta4(NeuAc-alpha8-NeuAc-alpha3)-Gal-beta4-Glu-Cer and NeuAc-alpha8-NeuAc-alpha3-Gal-beta4-Glu-Cer; wherein NeuAc represents sialic acid, Gal represents galactose, GalNAc represents galactosamine, Glu represents glucose and Cer represents N-fatty acyl-sphingosine. The marker can be used for clearly characterizing glioma tumors.

The invention provides a method for preparing monosialotetra-hexosylganglioside (GM1) by applying recombinant sialidase converted gangliosides (GLS). The method comprises the following steps: 1) providing a free recombinant sialidase which is a protein encoded by a base sequence shown in SEQ ID NO: 1; and 2) mixing the recombinant sialidase obtained in the step 1) with GLS so as to convert the GLS into the GM1. By virtue of total synthesis of a full-length gene of the sialidase, soluble expression of the sialidase is successfully realized in escherichia coli. The recombinant sialidase is high in specific activity and low in preparation cost. Moreover, the method can be further used for removing the inhibiting effect of sialic acid by adopting dialysis to in-situ separate a product sialic acid to promote reaction, so that the high concentration GLS is fully converted into the GM1.

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and / or an anti-allergic action.